Deans' stroke musings: Advances in Stroke Therapies Targeting Stroke Recovery

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, December 26, 2020

Advances in Stroke Therapies Targeting Stroke Recovery

With nothing in the abstract I would expect nothing useful to come from this. Maybe guidelines, NOT PROTOCOLS.

Advances in Stroke: Therapies Targeting Stroke Recovery

Lorie G. Richards

Steven C. Cramer

Originally published22 Dec 2020https://doi.org/10.1161/STROKEAHA.120.033231Stroke. ;0

Abstract

Stroke recovery therapies promote favorable neural plasticity, both during spontaneous recovery and the chronic phase. Activity-based therapies based on intense practice, some aided by integration of computers and telehealth, have shown promise. These studies emphasize key therapeutic variables such as dose, intensity, and timing. Preclinical drug studies have shown promise, but human translation has been challenged by identifying the target patient subgroup, requirements for concomitant training, and aligning biomarkers with preclinical evidence.

Footnotes

For Sources of Funding and Disclosures, see page 350.

The opinions expressed in this article are not necessarily those of the American Heart Association., Correspondence to: Lorie G. Richards, PhD, 520 Wakara Way, Salt Lake City, UT 84108. Email lorie.richards@hsc.utah.edu